Articles tagged with Antibodies
Glioblastoma, the deadliest form of brain cancer, has shown promise in treating with an engineered antibody that shuts down tumor growth. Researchers at Lombardi Comprehensive Cancer Center successfully tested the antibody in human cells and animal studies.
Patients with systemic lupus erythematosus (SLE) exhibit diminished immune responses to the flu vaccine, including lower antibody and cell-mediated responses. The study found that vaccination did not induce disease activity, but may increase morbidity and mortality due to influenza infection in these patients.
Researchers have developed an in-vitro antibody production technique to detect HIV infection earlier, reducing the diagnostic window period. This method promotes the synthesis and release of antibodies against HIV-1 prior to detection in plasma samples, leading to safer blood supply and improved diagnosis.
Researchers at La Jolla Institute have discovered the specific gene that triggers antibody production, a key step in mounting an immune response against viruses and pathogens. The finding has significant implications for developing new and more effective vaccines.
Researchers create highly stable chemical compounds that can bind to proteins with high affinity and selectivity, replacing traditional antibodies used in medical diagnostic tests. The technique involves a stepwise approach using in situ click chemistry, allowing for the creation of complex molecules in a relatively simple process.
A new study conducted by an Irish-led research team found no link between folic acid-related auto-antibodies and the risk of having a child with spina bifida. The study, which involved over 140 mothers of affected children, confirms previous findings that maternal folate status can prevent neural tube defects.
Dr. Jay Kolls receives $1.8M grant to explore antibody responses against Pneumocystis fungus, aiming to develop a vaccine to prevent or treat PCP. Preliminary studies show that carbohydrate antibodies participate in early clearance and regulate long-term immune responses.
Researchers found that HIV-1 damages the gut's B-cell arm of the immune system just days after transmission, disrupting its ability to fight infections. This damage affects both reactive and non-reactive B cells, leading to a weak response against pathogens like influenza.
Dr. Keri Smith has received a Career Development Award from the National Hemophilia Foundation to develop a therapy for people with Hemophilia A. Her approach involves altering chemical signals produced by T cells that trigger immune responses, making individuals more receptive to replacement Factor VIII.
Scientists have identified PLA2R, a protein found in normal human glomeruli, as the target antigen in idiopathic membranous nephropathy. This discovery holds promise for developing a blood test to replace kidney biopsies and determining which patients are most likely to benefit from immunosuppressive treatment.
A new computer model developed at MIT allows researchers to design more stable antibodies, reducing clumping and aggregation issues. The model identifies regions responsible for aggregation and enables mutation of amino acids to increase stability without affecting function.
A study of 115 young women with iron deficiency anemia found that serological screening for H. pylori and celiac disease increased gastroscopy compliance rates. The tests were confirmed by gastroscopy, which identified IDA-related GI causes in most cases.
A new device has been developed that can detect viruses and biological materials more quickly and cheaply than existing methods. The device uses synthetic antibody mimic proteins attached to nanowires to create a sharp measurement of current, allowing for rapid detection in under 10 minutes.
A new multimeric-L2 protein vaccine shows robust antibody responses and protection against human papillomavirus (HPV) infection in mice and rabbits. The vaccine has the potential to address the limited protection of current HPV vaccines against other HPV types, which cause cancer.
Researchers found that antibody interference can hinder vaccine effectiveness, proposing a new approach to design more powerful vaccines. They suggest intentionally developing a vaccine strain that differs from the anticipated infectious virus at specific sites.
A study of over 8,000 people found that higher blood levels of folic acid were associated with fewer reported allergies, less wheezing, and a lower likelihood of asthma. The researchers recommend further studies to confirm their results and establish safe doses.
Researchers have developed an engineered antibody called DTA-1 that helps the immune system overcome its natural reluctance to attack tumor cells. In a mouse model of melanoma, DTA-1 led to rejection of 50-60% of tumors by impairing regulatory T cells, providing new hope for improved cancer treatment options.
A team of researchers developed an antibody targeting FGFR3, which showed potent antitumor activity against human bladder cancer cells and t(4;14)-positive multiple myeloma cells. The antibody also demonstrated activity against normal FGFR3 and mutated forms associated with cancer.
Researchers have developed a new yogurt that fights stomach ulcer bacteria with almost vaccine-like effects. The yogurt contains an antibody that reduces bacterial activity, offering a potential alternative to antibiotics for treating gastritis and stomach ulcers.
Researchers at Rockefeller University have identified a diverse team of antibodies in slow-progressing HIV patients whose coordinated pack hunting knocks down the virus. These natural antibodies, produced by six people infected with HIV, show limited neutralizing ability when alone but become effective when combined.
Researchers at the University of Liverpool have determined the atomic structure of the binding between an antibody and a brain protein that could be key to treating vCJD. The study found that this antibody, ICSM18, has therapeutic potential in preventing brain cell infection and reversing early damage caused by the disease.
A new immune-system 'atlas' will improve doctors' ability to monitor transplanted organs and shed light on the mechanisms of gradual, cumulative kidney malfunction after transplant. The atlas allows for inexpensive, noninvasive blood tests that show whether a donated kidney is infected or accruing chronic injuries.
Researchers found significant correlations between serum levels of anti-tTG IgA and anti-DGP antibodies in untreated celiac disease patients. The study suggests an immune response difference to deamidated gliadin and tissue transglutaminase, supporting the hapten-carrier theory for anti-tTG IgA origin.
Patients treated with infliximab and adalimumab, a type of rheumatoid arthritis medication, are at an increased risk for developing herpes zoster (shingles). A significant association was found between treatment with these monoclonal anti-TNF-α antibodies and the development of shingles.
Scientists at Albert Einstein College of Medicine have developed radioimmunotherapy to target and destroy HIV-infected cells. The treatment, which uses antibodies attached to radioactive payloads, shows promise in laboratory and animal studies, and is currently being tested in pre-clinical trials.
Population immunity to measles was insufficient to interrupt transmission three years after a mass vaccination campaign in Zambia. Repeated mass vaccination campaigns are necessary to achieve high routine vaccine coverage and reduce measles deaths and illness.
Researchers have discovered a unique antibody that blocks the S1P receptor on T cells, reducing their numbers in the bloodstream and potentially treating autoimmune disorders such as colitis, lupus, and rheumatoid arthritis. The study's findings suggest a new horizon for reversing disabling and often fatal conditions.
Researchers at UCSF have identified a woman's immune system anomaly that may lead to breakthrough therapies for autoimmune diseases like rheumatoid arthritis and colitis. The discovery of antibodies blocking T-cell movement could result in more targeted treatments with lower risks of infections or tumors.
The Scripps Research team has developed a new technique to screen large antibody libraries against targets, enabling the acceleration of searches for new treatments against cancer and other diseases. This breakthrough allows for efficient access to the vast potential of synthetic antibodies.
Scientists have discovered a new mechanism by which the human immune system adapts to infections, involving 'cluster mutations' in antibody genes. This discovery fills a significant gap in our understanding of how we survive microbial invasions and may lead to new ways to prevent illnesses or make them less dangerous.
Researchers discovered that a 1966 RSV vaccine's defective antibodies failed to bind to the real virus, leading to severe disease. New findings could lead to the development of safer and more effective vaccines for RSV and other respiratory viruses.
A randomized clinical trial found that half-dose influenza vaccine produced similar antibody responses to full-dose vaccines in healthy adults. Women had a greater response to both doses, suggesting guidelines should consider sex as well as age. This study supports the validity of dose reduction strategies during vaccine shortages.
Researchers found that bavituximab, a PS-targeting antibody, can cure lethal virus infections in animal models of cytomegalovirus and Lassa fever. The drug showed potent anti-viral activity and may represent a new class of drugs for treating viral infections.
Researchers at MIT have developed a method to analyze single-cell responses to vaccination, providing a comprehensive picture of the immune system's ability to fight off infection. This breakthrough could lead to the development of new vaccines for diseases including HIV, fungal infections and antibiotic-resistant bacterial infections.
Researchers have developed a technique using soft lithography to create 'snapshots' of immune cell populations, offering insights into antibody diversity and potential for vaccine development. This innovation could lead to more effective diagnostic tools and personalized treatments.
A study found that a higher dose of flu vaccine boosts the immune response in people aged 65 and older, increasing antibody levels by 30-80% compared to the standard dose. This could lead to better protection against the flu for those most at risk.
The study found that the level of H. pylori IgG antibodies has limited value in diagnosing active peptic ulcer disease and does not show association with gastric mucosal morphology. A negative serology test result is reliable for excluding H. pylori infection, making it useful for screening purposes.
Sticky glue secreted by Staphylococcus aureus bacteria may hold the key to creating an effective vaccine against MRSA. Researchers have found that manipulating this natural compound can stimulate the right immune response, offering a potential solution to the growing problem of antibiotic-resistant infections.
A study of 50 healthy adult men found that black non-sensitized males had an average of 17.2% more HLA-sensitive B cells than white non-sensitized males, increasing their opportunity for antibody-mediated rejection. This increased number of B cells may be customized in treatments to lessen the likelihood of organ rejection.
Scientists have pinpointed the FCER1A gene as a major factor in allergic diseases, influencing IgE antibody production and leading to conditions like hay fever and asthma. The discovery has potential for guiding new drug development.
A virus that infects potatoes has been used to develop antibodies that can bind to the amyloid beta protein, a key contributor to Alzheimer's disease. Studies in mice have shown promising results, with the development of strong antibodies that can slow disease progression and improve cognitive function.
Researchers have identified low levels of naturally occurring antibodies as an increased risk factor for cardiovascular disease, particularly stroke in men. This breakthrough finding suggests that anti-PC antibodies play a crucial role in the development of cardiovascular disease.
Researchers developed an injectable vaccine grown in genetically engineered plants to treat follicular B-cell lymphoma, a chronic and incurable disease. The plant-grown vaccines lack side effects and could allow earlier, more aggressive management of the cancer.
Exhausted B cells hinder HIV-infected individuals' ability to clear the virus from their bodies. Researchers found that these cells produce low-quality antibodies, making it challenging to develop an effective vaccine.
Scientists discovered that HIV depletes functional B cells, which produce antibodies. The fatigued B cells overexpress the protein FCRL4, dampening their response to infection.
Researchers found a strong association between human herpesvirus 8 (HHV-8) infection and ketosis-prone type 2 diabetes mellitus (DM-2) in persons from sub-Saharan Africa. HHV-8 antibodies were present in 87.7% of patients with DM-2, compared to 15.1% of those without the condition.
Scientists at La Jolla Institute for Immunology discovered a previously unknown mechanism in how the body responds to viruses, illuminating a new approach to developing vaccines. The finding reveals that B cells and CD4 T cells recognize the same piece of the virus, narrowing down the search for antigens.
Researchers developed a promising new technique to track genetically engineered cells using antibody fragments as reporter genes, which could advance disease treatment. The technique offers several advantages over existing methods, including improved specificity and accuracy.
Researchers found that a chicken antibody behaves differently from its human counterpart, which sheds light on the origin of allergic reactions. The discovery could lead to designing drugs that alter the interaction between antibodies and white blood cells.
Researchers have developed a chemically modified protein that neutralizes inhibitor antibodies in people with Hemophilia A, offering a potential new treatment option. The modified protein, called electrophilic FVIII analog (E-FVIII), permanently inactivates these antibodies, paving the way for more effective blood clotting correction.
Researchers at the University of New Hampshire Glycomics Center have identified a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody. This discovery may lead to improved treatment options for autoimmune diseases such as lupus and rheumatoid arthritis.
Research found that thalassemic patients had a higher prevalence of anti-HAV IgG antibodies than healthy controls. This is unexpected, as previous studies showed lower rates in thalassemics. The study recommends active immunization for transfused thalassemia patients to reduce liver infections.
Researchers at the University of Michigan discovered a link between specific antibodies and oral health, finding that healthy individuals have higher antibody levels to a key protein in periodontal disease. This discovery could lead to improved treatment responses and prevention strategies.
Researchers in Uganda have discovered a new orthopoxvirus in red colobus monkeys, similar to those causing monkeypox and cowpox. The finding highlights the potential for unknown pathogens to emerge in wildlife and pose risks to human health.
Researchers at the University of Illinois have developed a new technique to image cells under an electron microscope, yielding a sharper picture of chromatin structure. This method allows for enhanced staining and structural preservation, enabling scientists to study chromatin packing and gene expression in high resolution.
A simple and fast screening technique has been developed to identify promising synthetic molecules that mimic therapeutic antibodies and can treat cancer at a lower cost. The new method screened over 300,000 peptoids and isolated five candidates that showed promise in treating human tumors.
A study published in Arthritis Research & Therapy found that a gluten-free vegan diet can lower cholesterol and oxidized LDL levels, while raising natural antibodies against phosphorylcholine in patients with rheumatoid arthritis. This may help protect against heart attacks and stroke.
New DNA vaccine technology targets DCs for enhanced immune response; studies in mice show improved protection against viruses and potential applications for cystic fibrosis modeling. Genetic manipulation creates large animal models of CF, providing new avenues for disease research.
New DNA vaccine data identified in mice shows increased immune response by targeting HIV protein gp41 to DCs with a single-chain Fv antibody. This approach induced stronger T cell responses and protected mice from the virus more efficiently than current DNA vaccines.
Researchers at ETH Zurich have developed a novel antibody test that can detect specific antibodies against Plasmodium falciparum's toxic sugar molecules. This test has the potential to protect adults from severe malaria and could also be used to develop a selective vaccine for infants under 5, who are most vulnerable to the disease.